Skip to main content

Advertisement

Table 2 Primary outcomes over the 12-week treatment period

From: Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study

  MSM (n = 25) Placebo (n = 25)   Significance for between group differences at follow-ups
  6 weeks 12 weeks Difference 0-12 wk [CI] 6 weeks 12 weeks Difference 0-12 wk [CI] Between group difference [CI] 0-6 wks 0-12 wks
WOMAC          
   Pain 35.5 ± 26.1 34.0 ± 24.5 -9.0 ± 24.0 [-18.9, 0.9] 47.1 ± 26.6 49.4 ± 20.8 3.5 ± 19.3 [-4.5, 11.5] 12.4 [0.0, 24.8] 0.20 0.05*
   Stiffness 39.2 ± 31.0 36.0 ± 26.2 -11.7 ± 30.7 [-24.3, 1.0] 52.9 ± 30.4 58.5 ± 24.2 15.5 ± 35.8 [0.7, 30.3] 27.2 [8.2, 46.2] 0.03* 0.01*
   Function 36.6 ± 23.7 33.1 ± 23.1 -7.7 ± 19.3 [-15.8, 0.3] 46.2 ± 25.1 54.3 ± 21.1 6.9 ± 17.0 [0.1, 13.9] 14.6 [4.3, 25.0] 0.51 0.01*
   Total 36.6 ± 23.9 33.3 ± 22.5 -8.4 ± 17.8 [-15.8, -1.1] 47.2 ± 24.5 53.5 ± 20.3 6.5 ± 17.0 [0.5, 13.5] 15.0 [5.1, 24.9] 0.26 0.00*
ALF 36.5 ± 16.6 36.9 ± 20.7 -6.8 ± 10.3 [-11.0, -2.5] 32.2 ± 10.6 33.9 ± 10.9 0.8 ± 4.9 [-1.2, 2.8] 7.6 [2.9, 12.2] 0.02* 0.00*
SF-36 59.8 ± 19.7 62.2 ± 20.3 8.1 ± 21.8 [-0.8, 17.1] 61.1 ± 16.2 54.5 ± 15.4 -3.4 ± 14.6 [-9.5, 2.6] -11.6 [-22.1, -1.0] 0.52 0.03*
VAS 3.30 ± 2.8 3.61 ± 2.9 -0.2 ± 3.2 [-1.5, 1.1] 5.22 ± 2.9 5.16 ± 2.22 0.6 ± 2.7 [-0.6, 1.7] 0.7 [-0.9, 2.4] 0.18 0.38
  1. Values are presented as mean ± SD.
  2. * The significance threshold was set at p ≤ 0.05. Intention to treat analysis was carried out with the last observation carried-forward method.
  3. CI = 95% confidence interval; MSM = methylsulfonylmethane; WOMAC = Western Ontario and McMaster Osteoarthritis Index graded from 0-100 mm, with 100 mm being the worst symptoms; ALF = Aggregated locomotor function in seconds; SF-36 = 36-item short-form health survey graded from 0-100, with 0 being the worst pain and quality of life; VAS = Visual-analogue-scale graded from 0-10 cm for pain, with 10 cm being the worst pain.